BioSpace News Archive

According to the report, the global pulse electromagnetic field (PEMF) therapy devices market was valued at US$ 550 Mn in 2020 and is anticipated to expand at a CAGR of 3% from 2022 to 2030.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022.

Assembly Biosciences, Inc. announced that it is discontinuing further development of its first-generation core inhibitor, vebicorvir, as it prioritizes clinical development of its next-generation core inhibitors, ABI-H3733 and ABI-4334, and advances its research pipeline.

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022 to discuss the company’s second quarter financial results.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022.

Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid nodule fine needle aspiration (FNA) biopsy samples.

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022.